Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

被引:144
|
作者
Chung, Jin-Haeng [2 ]
Rho, Jin Kyung [1 ]
Xu, Xianhua [2 ]
Lee, Jong Seok [3 ]
Yoon, Ho Il [3 ]
Lee, Choon Taek [3 ]
Choi, Yun Jung [1 ]
Kim, Hye-Ryoun [1 ]
Kim, Cheol Hyeon [1 ]
Lee, Jae Cheol [1 ]
机构
[1] Korea Canc Ctr Hosp, Korea Inst Radiol & Med Sci, Dept Internal Med, Seoul 139706, South Korea
[2] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Pathol, Gyeonggi Do, South Korea
[3] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Internal Med, Gyeonggi Do, South Korea
关键词
Epithelial to mesenchymal transition; EGFR; Resistance; Lung cancer; CELL LUNG-CANCER; KINASE INHIBITORS; SENSITIVITY; MUTATIONS; GEFITINIB; DETERMINES; ERLOTINIB; SURVIVAL; LINES;
D O I
10.1016/j.lungcan.2010.11.011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Epithelial-to-mesenchymal transition (EMT), which was related with an acquired resistance to gefitinib, was found in the A549 lung cancer cell line. However, the clinical feasibility of this finding is still questionable. Here, we investigated whether EMT could be detected in a more clinically suitable situation using patient's tumor and cells with deletion mutation on exon 19 of EGFR gene. Methods: HCC827 cell line was used to establish the subline resistant to EGFR-TKIs. The induction of EMT was analyzed by immunostainings and Western blots in resistant cells and biopsied tissue from a patient with acquired resistance to erlotinib. Migration and invasion assay was performed to characterize the resistant cells. EMT-related genes expression was evaluated by cDNA microarray. Phospho-receptor tyrosine kinase array analysis was carried out to find bypass activating signals such as MET. Results: We found that EMT developed in a lung cancer patient who had an acquired resistance to erlotinib while there were no known resistant mechanisms such as T790M and MET amplification. CL-387,785-resistant cells (HCC827/CLR) were obtained by long-term exposure to increasing concentrations of CL-387,785 (an irreversible EGFR-TKI). The morphological and molecular maker changes compatible with EMT were also found in HCC827/CLR cells. However, there were also no secondary T790M mutation and MET amplification. Furthermore, the activity of most of tested RTKs including receptor HER family was decreased suggesting that there was no bypass activating signal leading to resistance. These cells showed an enhanced capability for migration (similar to 1.6-fold) and invasion (similar to 2.8-fold). Conclusion: EMT should be considered as one of possible mechanisms for the acquired resistance to EGFR-TKIs in lung cancer cells. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:176 / 182
页数:7
相关论文
共 50 条
  • [1] Continued EGFR-TKIs treatment promotes the survival of elderly patients with acquired resistance to EGFR-TKIs therapy
    Wang, P.
    Zhang, D.
    Li, X. -M.
    Guo, X. -G.
    Sun, B. -J.
    Fang, X. -Q.
    Qu, G. -P.
    An, L.
    Liu, C. -T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2016, 20 (11) : 2450 - 2459
  • [2] Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition
    Zhou, Juan
    Hu, Qiaoting
    Zhang, Xi
    Zheng, Jihua
    Xie, Bo
    Xu, Zhiyong
    Zhang, Weimin
    ONCOLOGY REPORTS, 2018, 39 (04) : 1783 - 1792
  • [3] Cigarette smoking impairs the response of EGFR-TKIs therapy in lung adenocarcinoma patients by promoting EGFR signaling and epithelial-mesenchymal transition
    Liu, Ming
    Zhou, Chenzhi
    Zheng, Jian
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (10): : 2026 - 2035
  • [4] Loss of an EGFR-amplified chromosome 7 as a novel mechanism of acquired resistance to EGFR-TKIs in EGFR-mutated NSCLC cells
    Furugaki, Koh
    Iwai, Toshiki
    Moriya, Yoichiro
    Harada, Naoki
    Fujimoto-Ouchi, Kaori
    LUNG CANCER, 2014, 83 (01) : 44 - 50
  • [5] Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer
    Zhou, Juan
    Wang, Jinjing
    Zeng, Yunyun
    Zhang, Xi
    Hu, Qiaoting
    Zheng, Jihua
    Chen, Bei
    Xie, Bo
    Zhang, Wei-Min
    ONCOTARGET, 2015, 6 (42): : 44332 - 44345
  • [6] HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition
    Wang, Qi
    Li, Xuefei
    Ren, Shengxiang
    Su, Chunxia
    Li, Chunyu
    Li, Wei
    Yu, Jia
    Cheng, Ningning
    Zhou, Caicun
    LUNG CANCER, 2020, 147 : 99 - 105
  • [7] Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients
    Tudor, Roxana Aline
    D'Silva, Adrijana
    Tremblay, Alain
    MacEachern, Paul
    Morris, Don
    Brenner, Darren
    Kopciuk, Karen
    Bebb, Dafydd Gwyn
    PLOS ONE, 2017, 12 (08):
  • [8] Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR-TKIs Resistance
    Tian, Jin
    Shi, Zhiqi
    Zhao, Lili
    Liu, Peng
    Sun, Xiaojun
    Long, Lin
    Zang, Jianhua
    Xiao, Jun
    CLINICAL RESPIRATORY JOURNAL, 2024, 18 (12)
  • [9] Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
    Du, Xiaojing
    Yang, Biwei
    An, Quanlin
    Assaraf, Yehuda G.
    Cao, Xin
    Xia, Jinglin
    INNOVATION, 2021, 2 (02):
  • [10] Identification of Genomic Alterations Acquired During Treatment With EGFR-TKIs in Non-small Cell Lung Cancer
    Kubo, Naoki
    Harada, Taishi
    Shiraishi, Yoshimasa
    Nosaki, Kaname
    Nakagaki, Noriaki
    Takeshita, Masafumi
    Ouchi, Hiroshi
    Iwama, Eiji
    Tanaka, Kentaro
    Okamoto, Isamu
    Sasaki, Hiroyuki
    Nakanishi, Yoichi
    ANTICANCER RESEARCH, 2019, 39 (02) : 671 - 677